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Abstract
Methamphetamine (MA) is an addictive drug with neurotoxic effects on the brain
producing cognitive impairment and increasing the risk for neurodegenerative
disease. Research has focused largely on examining the neurochemical and
behavioral deficits induced by injecting relatively high doses of MA [30 mg/kg of
body weight (bw)] identifying the upper limits of MA-induced neurotoxicity.
Accordingly, we have developed an appetitive mouse model of voluntary oral MA
administration (VOMA) based on the consumption of a palatable sweetened
oatmeal mash containing a known amount of MA. This VOMA model is useful for
determining the lower limits necessary to produce neurotoxicity in the short-term
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1.743 mg/kg bw/hour during 3 hours, and an average of 5.23 mg/kg bw/day over
28 consecutive days on a VOMA schedule. Since this consumption rate is much
lower than the neurotoxic doses typically injected, we assessed the effects of long-
term chronic VOMA on both spatial memory performance and on the levels of
neurotoxicity in the hippocampus. Following 28 days of VOMA, mice exhibited a
significant deficit in short-term spatial working memory and spatial reference
learning on the radial 8-arm maze (RAM) compared to controls. This was
accompanied by a significant decrease in memory markers protein kinase Mzeta
(PKMζ), calcium impermeable AMPA receptor subunit GluA2, and the post-
synaptic density 95 (PSD-95) protein in the hippocampus. Compared to controls,
the VOMA paradigm also induced decreases in hippocampal levels of dopamine
transporter (DAT) and tyrosine hydroxylase (TH), as well as increases in dopamine
1 receptor (D1R), glial fibrillary acidic protein (GFAP) and cyclooxygenase-2
(COX-2), with a decrease in prostaglandins E2 (PGE2) and D2 (PGD2). These
results demonstrate that chronic VOMA reaching 146 mg/kg bw/28d induces
significant hippocampal neurotoxicity. Future studies will evaluate the progression
of this neurotoxic state.
Keywords: Neuroscience
1. Introduction
Methamphetamine (MA) abuse is a costly and detrimental health risk in the U.S.
and abroad. In the U.S., the number of individuals who reported abusing MA in
2012 was approximately 1.2 million people (4.7 percent of the population) (NIDA,
2013). Amphetamine-type stimulants (ATS) now rank second only to cannabis as
the most common illicit drugs used worldwide, representing approximately 34
million users (UN, 2008). North America continues to be a significant market for
ATS, particularly amphetamine and methamphetamine (UN, 2011). Based on these
statistics, it becomes increasingly important that we understand the risk factors
associated with MA addiction, and develop new animal models to better address
treatment outcomes for addicts. It is well known that MA abusers show a long-
lasting reduction in dopamine terminals and transporters, both of which increase
the risk for Parkinson’s Disease (McCann et al., 2008; Volkow et al., 2015).
Chronic MA abuse also results in neurodegeneration of frontal cortex, midbrain
regions and hippocampus, which are all associated with memory deficits
(Thompson et al., 2004). Additionally, an increase in markers of neuroinflamma-
tion, including activated microglia was reported in MA abusers (Sekine et al.,
2008). Several animal studies have recapitulated many of these neurochemical and
behavioral characteristics associated with MA abuse [reviewed in (Cadet and
Krasnova, 2009)]. Many animal studies show that neurotoxic or binge-dosing
regiments of MA produce rapid increases in microglia (LaVoie et al., 2004) and
glial fibrillary acidic protein (GFAP) levels within the striatum and hippocampus
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(Goncalves et al., 2010; Narita et al., 2005; Simoes et al., 2007) shortly after
administration.
While there are many MA paradigms for rodents currently used, what is needed is a
model that capitalizes on the voluntary MA consumption without the need for
conditioning to administer the drug or surgery that can restrict the types of
behavioral assessments used. Here we provide data on a voluntary oral
methamphetamine administration (VOMA) model useful for determining the
progressive nature of voluntary abuse-associated neurotoxicity in a rodent model.
Our goal was to assess the effectiveness of this VOMA model in producing
hippocampal-dependent memory and learning deficits, as well as MA-associated
neurochemical changes. To evaluate cognitive behavior we used the radial arm
maze (RAM), which is a hippocampal-dependent task (Jarrard, 1978; Olton and
Papas, 1979) used to assess both long-term reference and short-term working
memories (Braren et al., 2014).
Following behavioral assessments, we quantified changes in (1) dopamine-
related markers involving tyrosine hydroxylase (TH), dopamine transporter
(DAT), and the Dopamine 1 receptor (D1R); (2) glutamate receptor alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) GluA2 subunit; (3)
atypical protein kinase C iota/lambda (PKCι/λ), protein kinase Mzeta (PKMζ)
and the post-synaptic density 95 (PSD-95) protein; and (4) markers of
inflammation involving astrogliosis measured by GFAP, cycloxygenase-2
(COX-2), and prostaglandins (PG) E2, D2 and J2. We focused on these
molecular markers since MA selectively damages DA terminals and produces
excitotoxicity effects involving AMPA receptors (Bowers et al., 2010; Kalivas
and Volkow, 2011) in addition to elevated levels of inflammation (Simoes
et al., 2007). Astrogliosis is associated with MA neurotoxicity and several other
toxic insults in the brain (O'Callaghan and Sriram, 2005). Finally, as a synaptic
plasticity and memory marker, we focused on the atypical kinase PKMζ that is
important for spatial learning and long-term memory (Sebastian et al., 2013b;
Serrano et al., 2008), and which is increased concomitantly with improved
memory (Sebastian et al., 2013c) across several memory paradigms [reviewed
in (Sacktor, 2011)].
Our results show that 28d on VOMA produces significant deficits in hippocampal-
dependent short-term working and long-term reference learning on the RAM.
These behavioral deficits were associated with decreases in PKMζ, GluA2 and
PSD-95. VOMA also produced decreases in DAT and TH, with a concomitant
increase in D1R levels. Both GFAP and COX-2 increased, with decreases in PGE2
and PGD2. Thus, these results highlight the accumulating negative effects of
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2. Material and methods
2.1. Mice
All experimental conditions, housing, and drug administration procedures were
reviewed and approved by the Institutional Animal Care and Use Committee
(IACUC) of Hunter College. Male C57BL/6 mice from Taconic Farms (German-
town, NY) were purchased at 8 weeks of age. Mice were randomly assigned to 2
treatment conditions: MA (n = 5) and Control (n = 5). We have used similar sample
sizes to evaluate behavioral performance and protein expression as previously
reported (Braren et al., 2014; Sebastian et al., 2013a; 2013c). Mice were housed
individually to control for social effects of group housing (Weber et al., 2017) that
could affect the voluntary consumption of methamphetamine in our model. Mice
were kept on a 12/12 h light/dark cycle at the Hunter College animal facility for one
week prior to beginning any behavioral assessments with food and water ad libitum
prior to behavioral shaping. All housing conditions conform to the Hunter College
guidelines outlined by the IACUC.
2.2. Methamphetamine Treatment
We used a new voluntary oral methamphetamine administration (VOMA) model
over 28 consecutive days (experimental days 5–32). A sweetened oatmeal flake
(Maypo, Homestat Farm, Dublin, OH) was moistened with 8–10 μl of either MA
(2.5 mg/ml) or water. This produces a palatable sweetened oatmeal flake that
contains 1 mg MA/kg of body weight (bw) per serving (adjusted to mice ranging in
weight between 20–25 g). During MA administration, all mice were transferred to
individual mouse cages that were lined with absorbent paper. Each cage was
designated to a specific mouse throughout the experiment to ensure context
specificity. Cages were wiped clean and lined with fresh paper after each use. All
mice remained in their paper-lined cage for 30 min prior to treatment. During a 3
hour (hr) period, from 13:00 h to 16:00 h, mice were presented with individual MA
or water moistened oatmeal flakes. A new presentation was delivered in a clean
petri dish every 15 min. For each mouse, the number of consumed flakes during the
3 hr period was noted. Directly after VOMA, all mice were fed 4 g of mouse chow
daily at 18:00 h. This feeding schedule ensured that mice would be willing to
consume oatmeal flakes during the VOMA treatment time-window, for 28
consecutive days. This feeding schedule also circumvented the significant
circadian effects reported on VOMA administration (Keith et al., 2013), without
disrupting weight gain throughout the duration of the experiment.
2.3. Radial 8-arm maze shaping
The radial 8-arm maze (RAM) was used to assess both working memory and
spatial learning performance. The maze consists of a center platform (15.24 cm
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diameter) with 8 equivalently sized arms radiating outward. Each arm is 38 cm in
length, 6.35 cm wide and has a submerged food cup (2.0 cm diameter) at the end of
each arm. Maypo was mixed in water to make a wet mash used as a food reward
(0.02 g portions), as previously described for mice (Braren et al., 2014) and rats
(Serrano et al., 2008). Prior to working memory assessments, all animals were
shaped on the RAM during days 1–2 of the study. Mice were food restricted to
85% of free feeding weight before being placed on the RAM for 10 min to
acclimate to the maze and room cues. 1 hr later, all mice were given a second trial
with sweetened oatmeal in the food cups. After 1 day of shaping (2 trials per
day), mice were eating the food rewards and finding all 8 baits within a 15 min
maximum latency.
2.4. Working memory assessment
The working memory assessment (WMA) occurred during experimental day 37.
Mice were tested for 1 day (3 consecutive trials). Each trial started with all food
cups baited. To begin each trial, mice were confined for 30 s to the center platform
with a plastic cylinder. Between trials mice were confined to the center platform
while the arms were re-baited and the maze cleaned. The sequence of arms entered
to retrieve the food rewards was recorded. Mice were allowed to collect baits from
up to 3 sequential arms in any direction around the radial arm maze. Under rare
instances when a mouse adopted a chaining strategy by entering consecutive arms
in one direction around the maze, the 4th sequential arm was blocked to disrupt this
non-spatial strategy (Braren et al., 2014). Errors were recorded as re-entries into
arms where the food reward had already been collected. Working memory was
assessed by a % correct score for each trial, which was calculated by the number of
total arm entries required to collect all 8 food rewards divided by 8 (the total
number of rewards collected). All mice remained on the maze until all 8 baits were
collected. Maximum latency for each trial was set at 15 min.
2.5. Spatial learning/cognitive flexibility assessment
During experimental days 40–49, all mice were trained on a reference and working
memory version of the RAM as previously reported (Braren et al., 2014). This
paradigm had 4 baited and 4 un-baited arms in a pattern that was specific to each
animal and remained constant throughout the experiment. Mice were given 6
consecutive trials per day for 10 days (60 trials total). Between trials mice were
confined to the center platform while the arms were re-baited and the maze
cleaned. The sequence of arm entries was recorded. A reference memory error
reflected an entry into an arm that was never baited, while working memory errors
reflected re-entries into an arm where the bait had already been collected. Mice
were only allowed to enter up to 3 sequential arms to prevent the non-hippocampal
dependent chaining strategy. This version of the RAM required mice to learn room
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cues associated with the baited and un-baited arm sequence. The training room and
room cues were identical to that used for the WMA. 24 hrs after the last RAM trial,
all mice were given one reminder trial on the maze 1 hr prior to tissue retrieval.
Hippocampi from each mouse were removed, snap frozen and stored at −80 °C
until processed further.
2.6. Preparation of tissue fractions
Hippocampi were micro dissected and fractionated into cytosolic and synaptic
fractions as previously reported (Braren et al., 2014). Briefly, tissues were thawed
and homogenized in a TEE (Tris 50 mM; EDTA 1 mM; EGTA 1 mM) buffer
containing a Sigma Fast, protease inhibitor cocktail (Sigma Aldrich) diluted to
contain AEBSF (2 mM), Phosphoramidon (1 mM), Bestatin (130 mM), E-64 (14
mM), Leupeptin (1 mM), Aprotinin (0.2 mM), and PepstatinA (10 mM). Tissues
were homogenized in 200 μl of the TEE-homogenization buffer using 20 pumps
with a motorized pestle. Homogenates were transferred to Eppendorf tubes and
centrifuged at 3000 x g (5 min at 4 °C), to remove un-homogenized tissue. The
resulting supernatant was centrifuged at 100,000 g for 30 min. After ultracentrifu-
gation, the supernatant was collected and stored as the cytosolic fraction. The
remaining pellet was re-suspended in 100 μl of homogenizing TEE buffer
containing 0.001% Triton X–100, incubated on ice for 1 hr and then centrifuged at
100,000 g for 1 hr at 4 °C. The resulting supernatant was stored at the plasma-
membrane fraction. The resulting pellet was re-suspended in 50 μl of TEE buffer
and stored as the synaptic fraction (Nogues et al., 1994). The Pierce bicinchoninic
acid assay (BCA; Thermo Scientific, Rockford, IL, USA) was used to determine
protein concentration for each sample. Samples were reduced with 4x Laemmli
sample buffer equivalent to 25% of the total volume of the sample and then boiled
and stored frozen at −80 °C.
2.7. Immunoblots
Samples (20 μg) were loaded on to a Tris/Glycine 4–20% mini gel to resolve
GAPDH (37 kDa), α-Tubulin (55 kDa), PKMζ (55 kDa), PKCι/λ (68 kDa), GluA2
(98 kDa), PSD-95 (95 kDa), COX-2 (72 kDa), GFAP (53 kDa), TH (60 kDa), D1
(49 kDa) and DAT (69 kDa). Every gel contained 4 lanes loaded with the same
control sample designated as all brain sample (ABS). ABS was used to standardize
protein signals between gels. Gels were transferred to nitrocellulose membranes in
the IBlot® Dry Blotting System (Life Technologies; Carlsbad, CA, USA) for 7
min. Nitrocellulose membranes were then incubated in blocking solution
containing 5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1%
Tween-20 in TBS) for 30 min at room temperature. Samples were incubated
overnight with the following primary antibodies: GluA2 (1:2000; Chemicon,
Temecula, CA, USA), PKMζ/PKCι/λ (1:2000; Santa Cruz Biotechnology, Santa
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Cruz, CA, USA), GAPDH (1:2000; Abcam Inc., Cambridge, MA, USA), PSD-95
(1:1000; Cell Signaling Technology, Danvers, MA, USA), COX-2 (1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), GFAP (1:5000; Abcam Inc.,
Cambridge, MA, USA), TH (1:2000; ab152, Millipore, Billerica, MA, USA), D1
(1:2000; Abcam Inc., Cambridge, MA, USA), DAT (1:1000; EMD Millipore,
Temecula, CA, USA) and α-Tubulin (1:2000; Calbiochem, San Diego, CA, USA).
Membranes were washed in TBST for 20 min and probed with Horseradish
Peroxidase (HRP) conjugated secondary antibodies: Goat Anti-Mouse IgG (H +
L)-HRP Conjugate #1706516 (BioRad); Goat Anti-Rabbit IgG (H + L)-HRP
Conjugate #1706515 (BioRad); Rabbit Anti-Goat IgG H&L (HRP) (ab6741-
Abcam). Membranes were incubated with Enhanced Chemiluminescence (ECL)
substrate and exposed on CL-X Posure Film (Thermo Scientific; Rockford, IL,
USA). Films were scanned, and then densitometry was performed with NIH
ImageJ (Vierck et al., 2000).
2.8. Preparation of samples for prostaglandin quantification
For prostaglandin quantification, pre-weighed hippocampal tissues were homoge-
nized in 0.9 ml of phosphate buffered saline using a BeadBug microtube
homogenizer. Following homogenization, a 10-mg wet weight equivalent of
homogenate was removed and diluted to a final volume of 10 mg per 0.9 ml before
being further diluted 1:1 with 1% formic acid. Deuterated internal standards were
added (identified in italics in Table below) to the diluted homogenate and loaded
on a 2 ml Biotage SLE+ cartridge. After a 5 min incubation, the cartridges were
eluted twice with 6 ml of t-butlymethylether. The eluent was spiked with 20 μl of a
trap solution consisting of 10% glycerol in methanol with 0.01 mg/ml butylated
hydroxytoluene. The samples were dried for 45 minutes in a speed vacuum at 35
°C, the walls of the tubes were washed with 1 ml of hexane and re-dried until a
small aqueous residue remained. The residue was dissolved in 50 μl of 80:20
water:acetonitrile with 0.1 mg/ml butylated hydroxytoluene and spin filtered with a
0.22 μm Millipore Ultrafree® filter. Samples were transferred to vials and 30 μl of
sample were analyzed. Prostaglandin standard curves were spiked into PBS and
prepared identically to the samples. Area ratios were plotted and unknowns
determined using the slopes.
2.9. LC-MS/MS for prostaglandin quantification
Samples were analyzed using a 5500 Q-TRAP hybrid/triple quadrupole linear ion
trap mass spectrometer (Applied Biosystems, Carlsbad, CA) with electrospray
ionization (ESI) in negative mode. The mass spectrometer was interfaced to a
Shimadzu (Columbia, MD) SIL-20AC XR auto-sampler followed by 2 LC-20AD
XR LC pumps. The scheduled MRM transitions were monitored within a 1.5 min
time-window (supplemental Table 1). Optimal instrument parameters were
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determined by direct infusion of each analyte. The gradient mobile phase was
delivered at a flow rate of 0.5 ml/min, and consisted of two solvents, 0.05% acetic
acid in water and acetonitrile. The analytes were resolved on a Betabasic-C18
(100 × 2 mm, 3 μm) column at 40 °C using the Shimadzu column oven. Data was
acquired using Analyst 1.5.1 and analyzed using Multiquant 3.0.1(AB Sciex,
Ontario, Canada).
2.10. Statistics
For behavioral analyses, a repeated measure Two-Way ANOVA was used (Prism
GraphPad 7.0a Statistical Package, La Jolla, California). Post-hoc analyses used
Bonferroni-corrected t-tests. Western blot and PG mass-spec analyses between MA
and control treatments used independent t-tests. To characterize the generalizability
of our results and support the magnitude of effects in our studies independent of
sample size, effect sizes are reported. Effect sizes were calculated as generalized
eta squared (η2G) for behavioral data and Hedge’s unbiased g (g) for post-hoc
analyses and molecular data, using IBM SPSS Statistics for Mac (Armonk, NY:
IBM Corp.), and Microsoft Excel® as previously described (Lakens, 2013). For our
studies, benchmark coefficient thresholds for large effects (Lakens, 2013) were
taken into account and inflated in order to restrict significance. The thresholds for
large effect sizes in our studies were as follows: when η2G was 0.2 or higher, and
when g was 0.8 or higher. Effect sizes below these criteria were deemed moderate.
3. Results
3.1. Shaping and methamphetamine administration
The study began with shaping animals for a total of 2 days. After 4 total days of
acclimation, subjects were randomly assigned to either a water/control group or
MA for 28 consecutive days (days 5–32). The WMA was performed on day 37
after 5 days of forced abstinence from MA. This was followed by 10 days of
cognitive flexibility assessment on the reference/working memory version of the
RAM (days 40–49). Tissue was collected on day 50 (Fig. 1A). Over the 28d period
mice consumed an average of 5.23 mg/kg of MA/day. Fig. 1B reflects the average
weekly consumption of MA. Control mice ate every presentation of water-Maypo.
Fig. 1C shows the average weekly weights for both conditions. A two-way
ANOVA shows no significant difference between the groups [F(1,32) = 1.55, p
> 0.05; η2G = 0.023, non-significant effect size] indicating that the Maypo
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3.2. Radial- Arm-Maze working and reference memory assess-
ments
Fig. 2A shows the % correct scores in two separate analyses to illustrate the
differences in number of errors committed during a trial. Collecting the first 4
baits, when the working memory load is low, shows a much higher % correct score
compared to when the working memory load is high, collecting baits 5–8. An
overall 2-way ANOVA reflecting treatment condition (MA or saline) and baits
(1–4 or 5–8) shows a significant effect of bait [F (1,8) = 50.67, p < 0.001; η2G =
0.76, significant effect size]. The Bonferonni post-hoc analysis shows significant
within-group differences in both control (Bonferonni corrected t-test = 3.14, p <
0.05; g = 1.57) and VOMA (Bonferonni corrected t-test = 6.93, p< 0.001; g = 4.85)
mice when comparing group performances between collecting baits 1–4 and baits
5–8. Between groups, there were no significant differences between treatments for
baits 1–4 (Bonferonni corrected t-test = 0.39, p > 0.05; g = 0.23) In contrast,
VOMA produced a significant increase in working memory errors while
collecting baits 5–8 compared to controls (Bonferroni corrected t- test = 3.41, p
< 0.01; g = 1.92). Fig. 2B shows the latency to complete the working memory trials.
There were no significant differences between treatment conditions for latency to
complete working memory trials (Fig. 2B).
[(Fig._1)TD$FIG]
Fig. 1. Timeline for the 50d study, Average Methamphetamine (MA) Consumption and Body Weights.
(A) Days 1–2: behavioral shaping on RAM. Days 5–32: VOMA for 28d. Day 37: working memory
assessment. Days 40–49: cognitive flexibility assessment (spatial learning). Day 50: RAM test and
tissue harvest. (B) The total amount of MA consumed over the 28 day VOMA period, grouped into 4-
week averages for the Methamphetamine (Meth) group. (C) Mice were weighed during the consumption
period of VOMA. No significant differences were found between the two groups when analyzed by
two-way ANOVA [F(1,32) = 1.55, p > 0.05; η2G = 0.023, non-significant effect size].
Article No~e00509
9 http://dx.doi.org/10.1016/j.heliyon.2018.e00509
2405-8440/© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 3 shows the behavioral analyses for RAM acquisition across 10 training days
(experiment days 40–49 shown on graphs). An overall 2-way ANOVA for %
correct scores (Fig. 3A) shows a significant interaction effect of treatment on
training days [F(9,72) = 5.12, p < 0.01; η2G = 0.29] and time [F(9,72) = 33.38, p <
0.01; η2G = 0.73]. Post hoc tests show significant differences between treatment
conditions for training day 8 (Bonferroni corrected t-test = 3.45, p < 0.01; g =
1.97) and training day 9 (Bonferroni corrected t-test = 4.28, p < 0.01; g = 2.44). To
determine whether there are significant differences in asymptotic performance
level between groups, we assessed % correct scores during training days 6–10
(experiment days 45–49). This analysis shows an overall effect of drug treatment
[F(1,8) = 10.99, p < 0.05; η2G = 0.40], reflecting differences in the level of peak
performance. As predicted with asymptotic performance, there was no significant
effect of training days. Consistent with % correct score analyses, reference memory
errors shown in Fig. 3B reflect an overall significant interaction effect of treatment
on training days [F(9,72) = 3.75, p < 0.01; η2G = 0.25], and a significant effect of
training days [F (9,72) = 25.00, p< 0.01; η2G = 0.69]. During asymptotic
performance (training days 6–10 experiment days 45–49), reference memory errors
show an overall significant effect of treatment [F(1,8) = 13.8, p< 0.01; η2G = 0.33].
Analysis of working memory errors (Fig. 3C) shows an overall significant effect
on training [F(9,72) = 5.25, p < 0.01; η2G = 0.35], but no significant effect between
treatment conditions. During asymptotic performance (training days 6–10,
experiment days 45–49), there was a significant effect of treatment [F(1,8) = 5.513,
[(Fig._2)TD$FIG]
Fig. 2. VOMA impairs spatial working memory. (A) Two-way Repeated ANOVA showed an overall
effect of bait group (*** p < 0.001). Post hoc analyses reveal that both control and Meth mice
performed significantly worse to retrieve baits 5–8 compared to baits 1–4 (# indicates different from
control bait 1–4, p < 0.05; ! indicates different from Meth bait 1–4, p < 0.001). Baits 5–8 reveal a
significant difference between groups (^ indicates different from control in same bait condition p <
0.01). (B) There was no significant difference in latency to complete the trial between the groups.
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p < 0.05; η2G = 0.20] for working memory errors. Together the data in Fig. 3A-C
demonstrate that MA is significantly impairing the level of peak performance
across multiple analyses on this spatial learning task. Analysis of latency to
complete the training trials shows a significant interaction effect of treatment on
training days [F(9,72) = 4.92, p <0.01; η2G = 0.23] and an overall significant
decrease over training days [F(9,72) = 22.01, p < 0.01; η2G = 0.57]. Post-hoc tests
show a significant difference between treatment conditions on training day 1
(Bonferroni corrected t-test = 3.31, p < 0.05; g = 1.89).
[(Fig._3)TD$FIG]
Fig. 3. VOMA impairs spatial learning. All statistical analyses involved two-way ANOVA across 10
consecutive training days (experiment days 40–49 shown on graphs) and treatment conditions.
Differences between treatment conditions during asymptotic performance (training days 6–10,
experiment days 45–49) were analyzed separately. (A) % Correct shows a significant effect of training
days (^ p < 0.0001) and treatment conditions (# p < 0.0001). Bonferroni-corrected post hoc analyses
revealed significant differences between treatment conditions on training days 8 and 9, (experiment
days 47–48) (** p < 0.01; *** p < 0.001). During asymptotic performance (training days 6–10) there is
a significant treatment effect (! p < 0.05). (B) Reference memory errors show a significant effect on
training days (^ p < 0.01), a significant interaction (# p < 0.01), and a significant treatment effect
during asymptotic performance (training days 6–10, ! p < 0.01). (C) Working memory errors show a
significant effect of training days (^ p < 0.01), without a significant difference between treatment
conditions except during asymptotic performance (training days 6–10, ! p < .05). (D) Latency to
complete the trials show a significant effect of training days (^ p < 0.01), and a significant interaction
between treatment conditions (# p < 0.01). Bonferroni post-hoc tests show a significant difference
between treatment conditions on training day 1 (p<0.05).
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3.3. Hippocampal dopaminergic marker expression
Western blot analyses for dopaminergic markers showed a significant decrease in
cytosolic TH (t7 = 2.67, p < 0.05, g = 1.59; Fig. 4A). In the synaptic fraction, there
was a significant increase in D1R expression (t8 = 3.16, p < 0.01, g = 1.81,
Fig. 4B) and a decrease in synaptic DAT expression (t7 = 2.16, p < 0.05, g = 1.29,
Fig. 4C).
3.4. Hippocampal inflammatory marker expression
Inflammatory markers showed a significant increase of synaptic COX-2 (t8 = 1.93,
p < 0.05, g = 1.09, Fig. 5A) and cytosolic COX-2 (t7 = 2.03, p < 0.05, g = 1.211,
Fig. 5B). Cytosolic GFAP was also significantly elevated compared to controls (t7
= 3.86, p < 0.01, g = -2.30, Fig. 5C). GFAP and COX-2 increases suggest an
increase in proinflammatory activity in the hippocampus. MA-induced excitotoxi-
city can mediate increases of GFAP to allow for astrocyte activation in response to
MA-induced damage (McConnell et al., 2015). COX-2 is an inducible inflammatory
activator that can signal other pathways, including prostaglandin synthesis, which
can be protective or toxic to neurons (Figueiredo-Pereira et al., 2015). Fig. 5D-F
shows analyses of PGE2, D2 and J2 in picograms per milligram of wet weight of
tissue, indicating that PGD2 levels in control mice are at least 10-fold higher than
PGE2 and PGJ2. Both PGE2 and PGD2 significantly decrease (33% and 40%
respectively) with VOMA compared to controls (t8 = 3.95, p < 0.05; g = 2.26,
Fig. 5D. t8 = 3.73, p < 0.01; g = 2.13, Fig. 5E.). PGJ2, which is a PGD2 metabolite,
did not change significantly between treatment conditions (Fig. 5F).
3.5. Hippocampal synaptic plasticity marker expression
Compared to controls, VOMA produced a significant decline in glutamatergic and
synaptic plasticity markers including synaptic GluA2 (t6 = 8.53, p < 0.01, g =
[(Fig._4)TD$FIG]
Fig. 4. Chronic VOMA affects dopaminergic marker expression. Compared to controls, VOMA
decreases cytosolic TH (*p < 0.05; A). In the synaptic fraction, D1R significantly increased (**p <
0.01; B) and DAT significantly decreased (*p < 0.05; C) compared to controls. Representative blots
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5.24, Fig. 6A), synaptic PSD-95 (t8 = 3.38, p < 0.01, g = 1.93, Fig. 6B) and
cytosolic PKMζ (t8 = 2.55, *p < 0.05, g = 1.46, Fig. 6C). Cytosolic PKCι/λ
expression was not altered by VOMA treatment (Fig. 6D).
4. Discussion
4.1. VOMA as a model for studying MA addiction
VOMA is a new model for assessing both the chronic and acute effects of MA. MA
mixed in a palatable sweetened oatmeal mash provides a paradigm that does not
require surgery or conditioning. This model permits the animal unrestricted
movement that allows the experimenter to test various behavioral learning
paradigms. Our results demonstrate that chronic voluntary consumption of MA
results in significant spatial learning and memory deficits together with significant
changes in markers reflective of MA neurotoxicity. One of the main challenges in
MA research is designing an experiment that models aspects of human MA
addiction. We find that this VOMA model is useful for characterizing aspects of
addiction, as mice are able to titer the amount of drug administered, as reflected by
a consistent level of MA consumed over several weeks. Our results indicate that
the C57BL/6 mice will voluntary consume about 1.743 mg/kg bw/hr during a 3 hr
MA administration period. These data suggest that if 5 mg/kg bw MA was
delivered as a bolus dose to a mouse of this strain, even such a seemingly low dose
[(Fig._5)TD$FIG]
Fig. 5. Chronic VOMA increases neuroinflammation marker expression. In the synaptic (A) and
cytosolic (B) fractions COX-2 levels significantly increased compared to controls (*p < 0.05). (C)
Cytosolic GFAP increased compared to controls (**p < 0.01). See supplementary figures for original
images of blots. (D,E). PGE2 and PGD2 significantly decreased with VOMA compared to controls (*p
< 0.05; picograms/milligram). (F). PGJ2 expression did not change significantly between treatment
conditions. Representative blots show control (left band) and Meth (right band) treatments.
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is considerably higher than would be consumed voluntarily. Whether there is a
difference between an injection of 5 mg/kg bw compared to voluntarily consuming
this amount over a 3 hr period remains to be determined. Other MA models have
used appetitive paradigms (Keith et al., 2013) or drinking paradigms (Olsen et al.,
2013) that also demonstrate the short-term behavioral and neurochemical changes
associated with small doses of voluntary MA consumption. In our current study,
we examine the behavioral and neurochemical effects of chronic voluntary MA as
a way to more accurately model human MA addiction.
Throughout 28 days of VOMA, consumption rates increase over the first 2 weeks
and stabilize during the last 2 weeks. Previous self-administration models may only
reveal a trend to increase consumption due to the brief (2 weeks or less)
administration window. It is unclear how other self-administration models would
compare to VOMA across longer periods administration (4 weeks or more).
Moreover, it is important to consider how oral administration via a sweetened
medium might affect VOMA. Control mice in our study consumed every
presentation of water-Maypo (12 baits/day over 28 days), revealing a preference
for sweetened food by this mouse line. However, mice that consumed water-
Maypo laced with MA consumed less than half of the baits presented to them each
[(Fig._6)TD$FIG]
Fig. 6. Chronic VOMA decreases memory associated marker expression. In the synaptic fraction,
VOMA decreased (A) GluA2 (**p < 0.01) and (B) PSD-95 compared to controls (**p < 0.01). (C) In
the cytosolic fraction, VOMA decreased PKMζ compared to controls (*p < 0.05). (D) VOMA did not
significantly affect cytosolic PKCι/λ expression. Representative blots show control (left band) and Meth
(right band) treatments. See supplementary figures for original images of blots.
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day on average (see Results). This reveals that although a sugar preference could
motivate consumption of the MA-baits, mice rapidly adapt a strategy to consume
only as much MA-Maypo as they prefer. Mice on VOMA could still develop a
preference to MA as a result of the sweetened medium, but more work is needed to
determine this. Future studies should examine how the drug’s medium affects
consumption rates across long periods of MA access.
The use of an oral administration design is validated by previous work indicating
that the mean half-elimination life of oral MA is not significantly different from
that of the intravenous route, and that peak plasma concentration is delayed via the
oral route by 3 hrs in humans, compared to other routes (Cook et al., 1992; 1993).
This suggests that VOMA can model the delayed effects of MA on the brain, and
very adequately reveal the prolonged neurotoxic effects of the drug. Additionally,
previous work has revealed that although the injection route may be preferred by a
subset of highly-addicted individuals, non-injection routes make up a high
percentage of MA use in the United States (Novak and Kral, 2011). Nonetheless,
our study models oral MA administration, a route not likely preferred by MA-
addicted humans. Non-injection MA administration might be preferred by
individuals who have not yet developed an addiction. In order to fully understand
the distinct populations that abuse MA, more research is needed to clarify the onset
and progression of this addiction in humans as it relates to administration routes.
Future VOMA studies should examine the progression and relapse of MA
consumption in VOMA in order to accurately characterize the addictive phenotype
produced by our model.
4.2. MA-induces deficits in both spatial working and reference
memory performance
Our results show that total MA consumption of 146.4 mg/kg bw/28 consecutive
days result in a significant spatial working memory performance deficit. Our
previous study reports working memory deficits following neurotoxic doses of MA
(30 mg/kg bw delivered once per week for 2 weeks; 60 mg/kg bw total). These
working memory deficits developed over a 4 week abstinence period (Braren et al.,
2014). The working memory deficit observed in our current study may have
developed much earlier based on the levels of MA consumed. However, reports by
others suggest that lower doses of MA delivered chronically may have less harmful
or delayed cognitive effects, compared to bolus or neurotoxic doses (Marshall
et al., 2007; Simoes et al., 2007). The latter studies are consistent with the
protective effects observed when escalating doses of MA are delivered over days
that show reduced cognitive and neurochemical deficits, compared to neurotoxic
effects and the resulting cognitive deficits that result from a bolus dose (Belcher
et al., 2008; O'Neil et al., 2006; Riddle et al., 2002; Segal et al., 2003). Rapid
deficits in working memory performance identified 24 hrs following a neurotoxic
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dose of MA were previously reported (Simoes et al., 2007). However, without
repeated assessments over time, it is difficult to determine whether the working
memory deficits are long lasting or are reflective of the short-interval between MA
treatment and working memory testing. It is possible that shortly after MA
administration, mice are low on seeking novelty, an effect that is rectified weeks
after MA treatment as demonstrated in rat performance on the spontaneous
alternation task (Friedman et al., 1998).
Following the working memory assessment, mice were tested for cognitive
flexibility on the RAM. For this assessment, both working and reference memory
errors were scored. The MA treated mice exhibited a lower asymptotic
performance level for % correct scores and an increase in the number of reference
and working memory errors compared to mice given control treatment. This is
consistent with several other studies reporting spatial memory deficits following a
short abstinence period (Camarasa et al., 2010; Heysieattalab et al., 2016; Williams
et al., 2003). Others have shown that chronic use of MA can actually stave off MA-
induced deficits, which can then be initiated following long-periods of abstinence.
In this case, cognitive deficits were observed only following long-term abstinence
(1–4 weeks) (Belcher et al., 2005; Braren et al., 2014; Marshall et al., 2007; North
et al., 2013). The degree to which VOMA produces neuroprotection and/or can
delay the neurotoxic effects of MA remains to be determined.
4.3. Chronic VOMA decreases TH and DAT while increasing
D1R levels
Our previous studies revealed that acute neurotoxic doses of MA (2 × 30 mg/kg)
followed by 6 weeks of forced abstinence produce long-lasting decreases in
dopamine marker expression in the hippocampus (Braren et al., 2014). In our
current study, we found that VOMA for 28d also produced significant decreases in
these markers in the hippocampus. Previous work has shown that within days of
injecting neurotoxic doses of MA, the striatum exhibits a comparable decrease in
DA levels (Cappon et al., 2000; Fumagalli et al., 1998; Green et al., 1992; Guilarte
et al., 2003; O'Callaghan and Miller, 1994; Xu et al., 2005). MA-induced
reductions of TH and DAT in the striatum may indicate degeneration of DA axonal
terminals (Fukumura et al., 1998; Lorez, 1981; Ricaurte et al., 1982; 1984). This
explanation is supported by increased reactive astrogliosis associated with MA
treatment (Bowyer et al., 1994; Fukumura et al., 1998; Zhu et al., 2005). We
hypothesize that decreased DAT and TH together with an increase in astrogliosis
reflects a degeneration of DA terminals within the hippocampus. Whether our
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VOMA also induced a significant increase in D1R expression. This receptor is
known to mediate some of the MA-driven neurotoxic effects in the striatum
(Surmeier et al., 1995) and PFC (Gonzalez et al., 2016). Selective D1R antagonists
delivered prior to injections of binge doses of MA produce neuroprotective effects
against the MA-induced decreases in DA, TH and DAT (Xu et al., 2005).
Moreover, increases in MA-induced extracellular DA causes acute increases in
striatal glutamate as a result of D1R mediated disinhibition of corticostriatal
glutamate release (Mark et al., 2004). Together these findings suggest that
increased D1R expression is detrimental and/or exacerbates the neurotoxic damage
from MA. In contrast, it has been suggested that D1R activation is a
neuroprotective response. Dopamine suppresses glutamatergic hippocampal and
entorhinal neurotransmission by activation of the D1R (Behr et al., 2000).
Additionally, D1R activation can reduce NMDA receptor mediated Ca2+ currents
in hippocampal neurons, thus decreasing excitotoxicity (Lee et al., 2002). The D1R
also plays a role in reducing calcium currents in striatal neurons (Surmeier et al.,
1995), and in producing inhibition on N-type voltage-gated calcium channels
(Kisilevsky et al., 2008). Therefore, it is possible that alterations in other receptor
levels dictate whether increased D1R-levels are beneficial or detrimental. Future
studies will evaluate the changes in NMDA and mGluA receptor subunits, which
could add to understanding the consequences of these neurochemical changes. For
example, antagonism of NMDA, AMPA or metabotropic (mGluR5) receptors can
block MA-induced toxicity in the striatum (Battaglia et al., 2002; Golembiowska
et al., 2003; Marshall et al., 1993) or hippocampus (Farfel et al., 1992).
4.4. Neuroinflammatory marker levels increase in the hippo-
campus following chronic VOMA
We show that compared to controls, GFAP and COX-2 protein levels are elevated
in the hippocampus after 28d of VOMA. We propose that these changes in
inflammatory markers reflect a neurodegenerative response to MA. COX catalyzes
the conversion of arachidonic acid to prostaglandins (PG) and thromboxanes.
COX-1 is constitutively expressed, whereas COX-2 is induced upon stimulation by
various proinflammatory agents (endotoxins, cytotoxins) (Figueiredo-Pereira et al.,
2015; Smith et al., 2000). Elevated levels of COX-2 in the hippocampus increase
the extracellular concentration of glutamate, exacerbating glutamate-associated
excitotoxicity (Anneken et al., 2013; Bezzi et al., 1998; Kelley et al., 1999; Sang
et al., 2011). Our results are consistent with what is observed following neurotoxic
doses of MA (Tsuji et al., 2009). Conversely, COX-2 KO mice are resistant to
MA-dependent dopamine depletion in the striatum that results from high doses
(Thomas and Kuhn, 2005), suggesting that COX-2 up-regulation exacerbates the
neurotoxic effects of MA (Northrop and Yamamoto, 2013; Zhang et al., 2007).
Other reports show temporary GFAP increases in the hippocampus 24 h after
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neurotoxic doses of MA, which return to basal levels by 7d post injection
(Goncalves et al., 2010; Tsuji et al., 2009). These data suggest that the rapid
increases in GFAP induced by a neurotoxic dose of MA may reflect activation of a
neuroregenerative response, as this marker is expressed during neurogenesis in the
subgranular zone of the dentate gyrus (Zhu and Dahlström, 2007). Based on these
findings, it is possible that the accumulating (low doses) of MA during VOMA
prolong the short-term increase in GFAP that has been observed following
neurotoxic doses. Future studies should characterize the time course for the onset
and progression of GFAP expression in the hippocampus after VOMA.
Following a regimen of neurotoxic MA administration (4 × 10 mg/kg, 2 h apart, i.
p.), mice exhibit cytotoxic brain edema driven by increases in hippocampal and
striatal aquaporin-4 channels on astrocytes (Leitão et al., 2017). Increased GFAP
expression in the hippocampus following VOMA suggests that after chronic MA
abuse, the hippocampus is vulnerable to breakdown of the blood-brain barrier
resulting in cytotoxic edema. Astrocytes are one part of the complex neurovascular
niche and aquaporins play a pivotal role in regulating water and cerebro-spinal
fluid (CSF) flow into and out of the neuronal space (Amiry-Moghaddam et al.,
2004; Jessen et al., 2015). It is unclear how and when this dysregulation in
aquaporin-mediated shifts in water/CSF emerges and is resolved after chronic MA
abuse. Future studies should examine the role that aquaporin-mediated cytotoxic
edema plays in VOMA-induced neural and cognitive deficits.
PGE2 and PGD2 levels decrease following VOMA. PGD2 is the most abundant of
the PGs in the brain followed by PGE2, and both PGs induce secretion of nerve
growth factor and brain-derived neurotropic factor (Toyomoto et al., 2004). In
addition, both PGD2 and PGE2 were found to have neuroprotective effects in the
CNS (Masuda et al., 1986; McCullough et al., 2004; Taniguchi et al., 2007). These
studies suggest that decreased levels of PGD2 and PGE2, together with increased
expression of COX-2 could mediate a neurotoxic response to VOMA. It is possible
that the decrease in PGE2 reflects an increase in the 15-hydroxyprostaglandin
dehydrogenase (15-PGDH), a key enzyme in the metabolism of PGE2. An ALS
mouse model shows that 15-PGDH increases throughout the progression of the
disease specifically in GFAP positive astrocytes, while PGE2 only increased at the
end stage of the disease (Miyagishi et al., 2017). No other studies have measured
PGs in the hippocampus following MA. One study examined binge doses of MA
on PGE2 in the striatum showing no changes in PGE2 levels up to 48 hrs following
MA (Thomas and Kuhn, 2005). Further work is needed to delineate how these
different MA models affect PGs across various brain regions.
PGJ2 is a product of spontaneous dehydration of PGD2, which is the most
abundant prostaglandin in the brain (Hertting and Seregi, 1989) and the one that
changes the most under pathological conditions (Liang et al., 2005). PGJ2 is a
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highly neurotoxic prostaglandin (Li et al., 2004b), as it impairs both the ubiquitin-
proteasome pathway (Ogburn and Figueiredo-Pereira, 2006; Wang et al., 2006)
and mitochondrial function (Kondo et al., 2002). This PG also up-regulates COX-2
(Li et al., 2004a), most likely leading to a positive feedback loop between itself and
COX-2 (Figueiredo-Pereira et al., 2015). In supplementary studies, we have
observed that PGJ2 levels increase following 6 weeks of abstinence after acute
neurotoxic doses of MA (2 × 30 mg/kg; supplementary Fig. 1) and also increases
following 4 weeks of abstinence after a 2 week VOMA period (25 mg/kg total MA
consumed over 14d; supplementary Fig. 2). However, mice given 28d of VOMA
did not exhibit increases in PGJ2 (Fig. 5F). These data suggest that abstinence may
be playing a role in the increased expression of PGJ2. This finding is consistent
with previous studies indicating that abstinence from MA can exacerbate memory
deficits (Braren et al., 2014; North et al., 2013).
Our results suggest that the duration of abstinence and of MA-administration could
play opposing roles in promoting or suppressing PGJ2 levels in the hippocampus.
We hypothesize that a long period of abstinence from MA promotes PGJ2
expression, but that a longer period of MA administration mitigates it through
increased dopamine release. This hypothesis is consistent with the understanding
that dopamine is anti-inflammatory by inhibiting the activation of NOD-like
receptor containing Pyrin domain-3 (NLRP3) inflammasome by D1R activation
(Yan et al., 2015). Additional studies have shown that low doses of MA, which
increase dopamine release, are neuroprotective following oxygen-glucose
deprivation (Rau et al., 2016). However, it remains to be determined how
abstinence from MA contributes to increases in PGJ2.
4.5. MA decreases synaptic memory markers
Our results show that the levels of PKMζ and AMPA receptor subunit GluA2
decrease following VOMA. PKMζ is important for both late-phase LTP (Serrano
et al., 2005) and long-term memory maintenance across various learning
paradigms (Hsieh et al., 2016; Pastalkova et al., 2006; Sacktor, 2011; Serrano
et al., 2008). It is also important to note that increased GluA2 synaptic expression
is important for spatial memory (Migues et al., 2010; Sebastian et al., 2013c), as is
the trafficking of AMPA receptors by PKMζ (Ling et al., 2002; Yao et al., 2008).
These studies are consistent with the decline in PKMζ and GluA2 levels following
VOMA. We also assessed the protein levels of PKCι/λ, another atypical kinase
known to support spatial memory in the conditional-PKMζ KO mouse (Tsokas
et al., 2016), suggesting that PKCι/λ is active when PKMζ is compromised. PKCι/
λ expression was not significantly altered following VOMA, suggesting that
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GluA2 is one of the four AMPA receptor subunits impermeable to Ca2+ and is the
dominant heteromeric conformation (Geiger et al., 1995; Suzuki et al., 2003).
Reduced GluA2 levels were shown to increase neurotoxicity in amyotrophic lateral
sclerosis motor neurons (Lai et al., 2006; Van Damme et al., 2005). We
hypothesize that decreased GluA2 mediates the spatial learning impairment as well
as the elevated neurotoxic effects of MA. This is consistent with chronic MA
treatment. In contrast, studies by others examining acute doses of neurotoxic MA
report increased levels of GluA2 shortly after treatment (Simoes et al., 2007),
suggesting that elevated hippocampal GluA2 levels may be contributing to a
neuroprotective response by MA. However, after several weeks of abstinence,
hippocampal GluA2 levels return to baseline (Braren et al., 2014). Together these
results suggest that early after MA, hippocampal GluA2 increases as a
neuroprotective mechanism, while following chronic MA a decline in hippocampal
GluA2 could exacerbate MA neurotoxicity. These results are also consistent with
our behavioral data, indicating that GluA2 decline in the hippocampus could
underlie the spatial memory deficits found in VOMA mice.
Our results also show a significant decrease in PSD-95 protein levels. PSD-95 is
primarily located in the neuronal spine head and its density reflects synaptic
efficacy (Harris and Stevens, 1989). Moreover, increases in PSD-95 spine density
are associated with improved memory performance (Leuner et al., 2003; Marrone,
2007; Moser et al., 1994). These findings are consistent with the poor memory
performance and reduced hippocampal PSD-95 level in the MA treated mice. PSD-
95 levels also increase in the forebrain following MA-induced place preference
(Shibasaki et al., 2011), suggesting PSD-95 involvement in memory rather than a
secondary effect of MA-induced toxicity.
5. Conclusions
Our data demonstrate that chronic VOMA leads to significant deficits in spatial
learning and short-term working memory, which is consistent with reports by
others. Additionally, our results show that low doses of MA consumed over a 3 hr
period can produce significant neurotoxic changes in the hippocampus, reprodu-
cing the neurochemical effects observed in studies using bolus or neurotoxic doses
of MA. Chronic VOMA also leads to significant decreases in TH and DAT and an
increase in D1R expression as seen with neurotoxic and binge doses of MA. These
neurochemical changes are accompanied by increases in both COX-2 and GFAP
that were previously reported. In concert with the decline in PGE2 and PGD2
levels, these data may reflect extensive neurotoxic damage attributed to MA.
Finally, decreases in synaptic markers relevant to spatial long-term memory
involving both GluA2 and PKMζ are consistent with neurotoxicity-induced deficits
in working memory and spatial learning. The time course for the onset and
progression of these various neurochemical changes in the VOMA model remains
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to be determined. These data are consistent with what is observed in MA addicts
showing low levels of dopamine, DAT and TH associated with cognitive
impairment (Obermeit et al., 2013; Volkow et al., 2015). Together these studies
support the significance of this VOMA mouse model in identifying risk factors and
exploring potential remediation therapies against MA addiction.
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